Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 5Vipoma 4Carcinoma, Islet Cell 4Somatostatinoma 3Neuroendocrine Tumors 3Intestinal Obstruction 3Insulinoma 3Glucagonoma 3Gastrinoma 3Carcinoma, Hepatocellular 3Thymoma 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Meningioma 2Diarrhea 2Carcinoma 2Carcinoid Tumor 2Adenoma, Islet Cell 2Weight Loss 1Waldenstrom Macroglobulinemia 1Vomiting 1Recurrence 1Rectal Neoplasms 1Primary Inoperable Thymoma 1Pleural Effusion 1Pheochromocytoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Bevacizumab 23Sorafenib 20Doxorubicin 14Gemcitabine 11durvalumab 10Oxaliplatin 10Fluorouracil 10Cisplatin 10Capecitabine 9Nivolumab 8pembrolizumab 6Sunitinib 6tremelimumab 5atezolizumab 5Radiofrequency Ablation 5Neoadjuvant Therapy 5Leucovorin 5lenvatinib 4aldesleukin 4Thalidomide 4Radiotherapy 4Radiosurgery 4Everolimus 4Erlotinib Hydrochloride 4Drug Therapy 4Carboplatin 4toripalimab 3regorafenib 3camrelizumab 3apatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liver Neoplasms × Octreotide × Clear all
NCT00257426 2012-02-14

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
31 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡